Vitaflo signs new in-licensing agreement for Nordic countries
Navamedic's fully owned subsidiary Vitaflo Scandinavia AB has signed a new in-licensing agreement with OrphaSwiss GmbH for marketing of two products in Sweden, Denmark, Norway and Finland. The products fall within the knowledge areas pain and alcohol/heroin abusement, respectively. Vitaflo already represents OrphaSwiss in the knowledge area alcohol/heroin abusement with the product Naltrexone Vitaflo. Naltrexone Vitaflo is the market leader in its segment in Sweden.
"We are very pleased to see that our new subsidiary continues its strong record of signing new in-licensing agreements and expanding its portfolio. It is particularly encouraging to see that OrphaSwiss, who is already Vitaflo's partner on Naltrexone, demonstrates continued trust in Vitaflo as it's distributor in the Nordic countries", says CEO in Navamedic Øyvind W. Brekke.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.